US9561197 — Methods of therapeutic monitoring of phenylacetic acid prodrugs
Method of Use · Assigned to Horizon Therapeutics LLC · Expires 2030-09-22 · 4y remaining
What this patent protects
This patent provides methods for adjusting the dosage of certain phenylacetic acid prodrugs, such as HPN-100 and PBA, based on plasma measurements.
USPTO Abstract
The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.
Drugs covered by this patent
- Ravicti (GLYCEROL PHENYLBUTYRATE) · Horizon Therap Us
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1383 |
— | Ravicti |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.